ƒAAƒJAƒTAƒ^AƒiAƒnAƒ}Aƒ„Aƒ‰Aƒ
ˆãŠwŠÖŒW‚Ö–ß‚é
- ¤•i–¼
- ‰pŽš¤•i–¼
- ˆê”Ê–¼
- Ȇ
- Œ`ó
- Ž¡—ÖړIAŒø”\EŒø‰Ê
- »‘¢Œ³
- ””„Œ³
@
- ƒAƒVƒmƒ“
- Acinon
- ƒjƒUƒ`ƒWƒ“»Ü
- ƒJƒvƒZƒ‹150
- H2Žó—e‘ÌhRÜ(H2 Blocker)
- ˆÝ’×á‡A\“ñŽw’°’×á‡A‹t—¬«H“¹‰Š
- ƒC[ƒ‰ƒCEƒŠƒŠ[ŽÐ
- “ú–{ƒC[ƒ‰ƒCEƒŠƒŠ[Дޮ‰ïŽÐAƒ[ƒŠƒAV–òH‹ÆŠ”Ž®‰ïŽÐ
- ƒAƒZƒiƒŠƒ“
- Acenalin
- ƒVƒTƒvƒŠƒg»Ü
- ù/×—±
- Á‰»ŠÇ‰^“®•ŠŠˆ’²®Ü
- ƒ„ƒ“ƒZƒ“‹¦˜aДޮ‰ïŽÐ
- ‹¦˜a”yДޮ‰ïŽÐ
- ƒAƒvƒŒ[ƒX
- Aplace
- ƒgƒƒLƒVƒsƒh
- ù/×—±
- ˆÝ‰ŠEˆÝ’×ᇎ¡—ÃÜ
-
- ˆÇ—Ñ»–òДޮ‰ïŽÐ
- ƒAƒ{ƒrƒX
- ƒAƒ‹ƒTƒ‹ƒ~ƒ“
- ƒAƒ‹ƒ^ƒbƒg
- Altat
- ‰–Ž_ƒƒLƒTƒ`ƒWƒ“ƒAƒZƒ^[ƒg
- ƒJƒvƒZƒ‹75
- H2Žó—e‘ÌhRÜA’×ᇂȂÇ
- ’é‘‘ŸŠíДޮ‰ïŽÐ
- ’é‘‘ŸŠíДޮ‰ïŽÐ
- ƒCƒTƒƒ“
- ƒCƒgƒŠƒ][ƒ‹
- Itrizole Cap.50
- ƒCƒgƒ‰ƒRƒiƒ][ƒ‹
- ƒJƒvƒZƒ‹50
- ŒoŒûR^‹ÛÜ
- ƒxƒ‹ƒM[Eƒ„ƒ“ƒZƒ“ƒtƒ@[ƒ}ƒX[ƒeƒBƒJ
- ƒ„ƒ“ƒZƒ“‹¦˜aДޮ‰ïŽÐA‹¤˜a”yДޮ‰ïŽÐ
- ƒCƒ“ƒgƒƒ“A
-
-
- ’ŽË‰t
- ƒCƒ“ƒ^[ƒtƒFƒƒ“ƒ¿-2b
- ƒVƒFƒŠƒ“ƒOEƒvƒ‰ƒEДޮ‰ïŽÐ
- ƒVƒFƒŠƒ“ƒOEƒvƒ‰ƒEДޮ‰ïŽÐ
- ƒEƒ‹ƒO[ƒg
- Ulgut
- ‰–Ž_ƒxƒlƒLƒT[ƒg@ƒx[ƒ^ƒfƒXƒN
- ƒJƒvƒZƒ‹
- ˆÝ”S–Œ–hŒä‹@\‘‹AˆÝ‰ŠEˆÝ’×ᇎ¡—ÃÜ
- ‰––ì‹`»–òДޮ‰ïŽÐ
- ‰––ì‹`»–òДޮ‰ïŽÐ
- ƒEƒ‹ƒ\
- Urso
- ƒEƒ‹ƒ\ƒfƒXƒIƒLƒVƒR[ƒ‹Ž_
- @/è÷—±
- ŠÌE’_EÁ‰»‹@”\‰ü‘PÜ
- “Œ‹ž“c•Ó»–òДޮ‰ïŽÐ
- “Œ‹ž“c•Ó»–òДޮ‰ïŽÐ
- ƒEƒ‹ƒ\ƒTƒ“
- Urso
-
- ù50mg
- ŠÌE’_EÁ‰»‹@”\‰ü‘PÜ
- “Œ‹ž“c•Ó»–òДޮ‰ïŽÐ
- “Œ‹ž“c•Ó»–òДޮ‰ïŽÐ
- ƒGƒgƒLƒVƒXƒNƒŒƒ[ƒ‹
- Aethoxysklerol 1%Inj.
- 1%ƒ|ƒŠƒhƒJƒm[ƒ‹»Ü
- 1%’ŽË‰t
- H“¹Ã–¬áŽd‰»ÜAEIS—pBAS‚Æ—ª‚·B
- Дޮ‰ïŽÐƒJƒCƒQƒ“
- Дޮ‰ïŽÐƒJƒCƒQƒ“
- ƒGƒjƒ}ƒNƒŠƒ“
-
-
-
- ‘å’°“àŽ‹‹¾ŒŸ¸H
-
- –xˆä–ò•iДޮ‰ïŽÐ
- ƒGƒtƒI[ƒƒC
- FOY
- ’ŽË—pƒƒVƒ‹Ž_ƒKƒxƒLƒT[ƒg
- ’
- ’`”’•ª‰ðy‘f‘jŠQÜ
- ¬–ì–ò•iДޮ‰ïŽÐ
- ¬–ì–ò•iДޮ‰ïŽÐ
- ƒGƒŒƒ“ƒ^[ƒ‹
- Elental
-
-
- ¬•ª‰h—{Ü
-
- ƒwƒLƒXƒgEƒ}ƒŠƒIƒ“Eƒ‹ƒZƒ‹Š”Ž®‰ïŽÐ
- ƒIƒ[ƒbƒNƒX
- ƒIƒƒvƒ‰[ƒ‹
- Omepral
- ƒIƒƒvƒ‰ƒ][ƒ‹»Ü
- ù
- Proton Pump Inhibitor(PPI)AR’×á‡Ü
- ƒXƒEƒF[ƒfƒ“EƒAƒXƒgƒ‰ŽÐiƒAƒXƒgƒ‰ƒWƒƒƒpƒ“j
- “¡‘ò–ò•iH‹ÆŠ”Ž®‰ïŽÐ
- ƒIƒƒvƒ‰ƒ]ƒ“
- Omeprazon
- ƒIƒƒvƒ‰ƒ][ƒ‹
- ù
- Proton Pump Inhibitor(PPI)AR’×á‡Ü
- ƒXƒEƒF[ƒfƒ“EƒAƒXƒgƒ‰ŽÐ
- ‹g•x»–òДޮ‰ïŽÐ
ƒAAƒJAƒTAƒ^AƒiAƒnAƒ}Aƒ„Aƒ‰Aƒ
–ß‚é
(C)masao.suda@nifty.ne.jp
memo